to edit- U of MN OBGYN template

Welcome to the

University of Minnesota Division of Gynecologic Oncology!

Community Involvement Committee

Research

Training Sites

Martina Bazzaro, PhD

Tim Starr, PhD

Amy Skubitz, PhD

Regions Hospital

Emil Lou, MD, PhD

S. Ramakrishnan, PhD

Fellow Research Publications

Saint Paul

Vacation Policy

Surgical Experience

Park Nicollet Methodist Hospital

U of MN Medical Center

East Bank

West Bank

St. Louis Park

• 20 PTO days/year for years 1 & 2

• 25 PTO days for year 3

• Can take in 1/2 day increments up to 1 week per block

• Conferences do not count against PTO

Colleen Rivard, MD

• Presentations: 8, including ACS, NSQIP, SGO, IGCS, WAGO
• Publications: 11 (8 as first author)

Elizabeth Dickson, MD

• Presentations: 11, including SGO, ACS, AACR, WAGO
• Publications: 9 (4 as first author)

Jori Carter, MD

• Presentations: 16, including SGO, ASCO, IGCS
• Publications: 12 (9 as first author)

Rajul Kothari, MD

• Presentations: 8, including WAGO, SGO
• Publications: 6 (5 as first author)

Research Grants

• American Cancer Society
• United States Department of Defense
• Society of Gynecologic Oncology
• Susan G. Komen Breast Cancer Foundation
• Minnesota Ovarian Cancer Alliance
• TESARO
• Foundation for Gynecologic Oncology/ME STRONG
• Minnesota Partnership for Biotechnology and Medical Genomics

Clinical Experience

Twin Cities

St. Paul

Minneapolis

Program Basics

By the Numbers...

• Wide variety of pathology
• Major referral center for northern Midwest region
• Diverse patient population

Minnesota!

Down Time

• 3-year fellowship
• 1 fellow per year
• 3 hospitals

Estimated Salary

• PGY5: $59,081
• PGY6: $61,155
• PGY7: $63,111

Faculty

Other Resources

Other Great Things About Our Program

Previous Fellows

• $1200 yearly administrative stipend
• $7500 research fund
• Department laptop

Breakdown of Rotations by Year

Year 2

By the Numbers...

Year 1

• No OB call!!!
• Moonlighting allowed
• Opportunities for international work
• Cultural and socioeconomic diversity of patient population and community
• Affordable cost of living

• 2 months protected research time
• 1 month SICU
• 1 month Radiation Oncology
• 8 months on Gyn Onc service

• 2 months on the Gyn Onc service
• 10 months of protected research time
• Optional graduate courses in Biostatistics and Cancer Biology

Elizabeth Dickson, MD Colleen Rivard, MD Jori Carter, MD Colleen Evans, DO

Aurora Health University of Minnesota Virginia Commonwealth Essentia Health

Milwaukee, WI University Duluth, MN

Year 3

Thanasak Sueblinvong, MD Rajul Kothari, MD Sajeena Thomas, MD

Kaiser Permanente University of Illinois University of Rochester

University of Hawaii Chicago, IL Rochester, NY

• 1 month Colorectal Surgery
• 11 months Gyn Onc service

Annie Tan, MD Hyung Suk Ryu, MD Justin Chura, MD Joseph Ivy, MD

Minnesota Oncology Mercy Medical Center Cancer Treatment Center Private Practice

Minneapolis, MN Baltimore, MD Philadelphia, PA Rogers, AR

Current Fellows

Other Members of

Our Team

Sue Petzel, PhD Dona Maki, RN Cara Miller, MSN, CNP

Psychologist,UMP UMP UMP

Tanya Pulver, MD

Year 2

Michelle Glasgow, MD

Year 3

Residents

Michelle Glasgow, MD

Basic Science/Translational Research

Simulation Training

Kandic Tolic, NP Kirsten Malvey, NP Pam Dalager, RN

Regions UMP UMP

Mihae Song, MD

Year 1

Other Program Benefits

• 9 residents per year (36 total)
• Gyn Onc rotation coverage:
• 1 resident from each class on UMMC service (1 on night float; intern covers floor)
• 4th-year resident at Regions
• 3rd-year rotation at Methodist

• Free parking at all sites
• Meal cards
• Medical and dental
• Life insurance
• Liability and disability insurance
• Paid maternity/paternity leave

• UC Irvine Advanced Course in Cytoreductive Surgery
• Cadaver Lab
• DaVinci Xi Simulator

• Development of a Mouse Model of Ovarian Cancer (Thesis, Dr. Starr)
• Objective: Design a mouse model to simultaneously test multiple agents against various genetic mutations

• Changes in Gene Expression after NACT in Ovarian Cancer (Dr. Starr)
• Objective: Develop genetic profiles which may predict which patients respond well/poorly to NACT

• Impact of Chemoradiation on the Urinary Microbiome in Women with Cervical Cancer (Drs. Teoh, Fok, and Yuan; funded by SGO ME-STRONG grant)
• Objective: Describe the effect of primary chemoradiation on the urinary microbiome

• Correlation of L1CAM Expression and Clinical Outcome in Stage I Endometrial Cancer (Drs. Winterhoff, Khalifa, and Pulver)
• Objective: Determine if those patients with stage I EAC and L1CAM expression have poorer outcomes than patients with the same stage EAC without L1CAM expression

Tanya Pulver, MD

Basic Science/Translational Research

Administrative Staff

• Evaluation of USP14 as a biomarker for recurrence in early-stage endometrial adenocarcinoma (Thesis, Dr. Bazzaro)

• Personalized mouse models of chemotherapy resistance in ovarian cancer (Drs. Starr and Bazzaro)

• Molecular analysis of endometrial hyperplasia, endometrial carcinoma, and benign endometrium (Dr. Geller, Dr. Bakkum-Gamez- Mayo Clinic)

• Genomic Characterization of Endometrial Cancer (Dr. Winterhoff, Dr. Konecny- UCLA)

• Correlation of L1CAM Expression and Clinical Outcome in Stage I Endometrial Cancer (Drs. Winterhoff, Khalifa, and Glasgow)

Kit Brown Deb Egger-Smith

Michelle Glasgow, MD

Clinical Projects

Palliative Care Training Workshop

Conferences

Michelle Glasgow, MD

Clinical Projects, continued

• Bi-weekly Pathology review at Regions
• Bi-weekly Radiation Oncology conference
• Weekly Gyn Onc conference
• Division Education Day every six weeks
• Fall and Spring Research Symposia
• Israel teleconference

Questions?

Drew Rosielle, MD Elizabeth Uchitelle, MD

• Anal dysplasia in Women with Genital Dysplasia (Dr. Geller)
• Objective: Identify risk factors for anal dysplasia in women with different degrees of dysplasia, link with HPV status; ultimate goal is to develop a model to predict which women with genital dysplasia should be screened for anal dysplasia

• Impact of Metformin on Outcomes in Women with Cervical Cancer Treated with Primary Chemoradiation (Dr. Teoh)
• Objective: Prior chart review showed better outcomes in this population of women who had diabetes. Determine if metformin (compared with no agent for DM or insulin) impacts survival

• Social Media to Reduce Postoperative Admissions (Dr. Teoh)
• Objective: Evaluate impact of mobile app in reducing 30-day readmissions, reducing patient self-report of complications, and in improving patient satisfaction with pre- and post-operative care

Tanya Pulver, MD

• Postoperative Readmissions following Ileostomy Formation among Patients with a Gynecologic Malignancy (Drs. Argenta and Teoh)
• Objective: Evaluate the incidence and reasons for readmission within 30 days following ileostomy in women with gyn malignancy

• Long-term follow-up of a Phase II Trial of Multimodal Therapy Given in a "Sandwich" Method for Stage III, IV, and Recurrent Endometrial Cancer (Dr. Geller)
• Objective: Review long-term PFS/OS from an initial Phase 2 trial on Sandwich Protocol, and to determine associated long-term lymphedema rates

• Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival? (Dr. Argenta, Dr. Silasi from Yale)
• Objective: Evaluate the surgical and oncologic outcomes in patients with stage I and II USC staged via minimally invasive surgical approaches compared with laparotomy

• Benefits Associated with Use of HIPEC at First Recurrence in Ovarian Cancer: An Update (Dr. Argenta)
• Objective: Compare survival in patients treated with HIPEC at first recurrence with the survival of patients treated at first recurrence with secondary cytoreductive surgery (without HIPEC) and/or systemic chemotherapy

Clinical Projects

Research Conferences and Meetings

• Effect of early Palliative Medicine referral on in-hospital mortality among Gynecologic Oncology patients (Dr. Carson)

• Identification of risk factors for readmission within 30 days of surgery among Gynecologic Oncology patients (Dr. Carson)

• Effect of chemotherapy on the rectal microbiome of patients with ovarian cancer (Drs. Carson, Ramakrishnan, and Rivard)

• Cervical cancer and HIV infection among women in Southern Province, Rwanda (Dr. Ghebre)